Biogen has abandoned the development and commercialization of aducanumab (Aduhelm), its controversial Alzheimer’s disease (AD) drug, citing the need to shift resources to other treatments for the brain disorder.
“This decision is not related to any safety or efficacy concerns,” the company said in a statement (bit.ly/485Vk1y). “A large portion of the resources released resulting from termination of the Aduhelm program will be redeployed in Biogen’s AD